Purified anthocyanin supplementation reduces dyslipidemia, enhances antioxidant capacity, and prevents insulin resistance in diabetic patients

J Nutr. 2015 Apr;145(4):742-8. doi: 10.3945/jn.114.205674. Epub 2015 Feb 4.

Abstract

Background: Oxidative stress plays an essential role in the pathogenesis of type 2 diabetes. Anthocyanin, a natural antioxidant, has been reported to reduce oxidative stress and to attenuate insulin resistance and diabetes in animal models; however, the translation of these observations to humans has not been fully tested.

Objective: This study was designed to investigate the effects of purified anthocyanins on dyslipidemia, oxidative status, and insulin sensitivity in patients with type 2 diabetes.

Methods: A total of 58 diabetic patients were given 160 mg of anthocyanins twice daily or placebo (n = 29/group) for 24 wk in a randomized, placebo-controlled, double-blind trial. Participants and investigators were masked to treatment allocation.

Results: Anthocyanin supplementation significantly decreased serum LDL cholesterol (by 7.9%; P < 0.05), triglycerides (by 23.0%; P < 0.01), apolipoprotein (apo) B-48 (by 16.5%; P < 0.05), and apo C-III (by 11.0%; P < 0.01) and increased HDL cholesterol (by 19.4%; P < 0.05) compared with placebo after the 24-wk intervention. In addition, patients in the anthocyanin group showed higher total radical-trapping antioxidant parameter and ferric ion reducing antioxidant power values than did patients in the placebo group (both P < 0.05). Serum concentrations of 8-iso-prostaglandin F2α, 13-hydroxyoctadecadienoic acid, and carbonylated proteins in patients in the anthocyanin group were significantly less than in patients in the placebo group (23.4%, 25.8%; P < 0.01 and 20%; P = 0.022, respectively). Furthermore, supplementation with anthocyanin lowered fasting plasma glucose (by 8.5%; P < 0.05) and homeostasis model assessment for insulin resistance index (by 13%; P < 0.05), and elevated serum adiponectin (by 23.4%; P < 0.01) and β-hydroxybutyrate (by 42.4%; P = 0.01) concentrations compared with placebo supplementation.

Conclusion: These findings demonstrate that anthocyanin supplementation exerts beneficial metabolic effects in subjects with type 2 diabetes by improving dyslipidemia, enhancing antioxidant capacity, and preventing insulin resistance. This trial was registered at www.clinicaltrials.gov as NCT02317211.

Keywords: anthocyanin; antioxidant capacity; dyslipidemia; insulin resistance; type 2 diabetes.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • 3-Hydroxybutyric Acid / blood
  • Aged
  • Anthocyanins / administration & dosage*
  • Anthocyanins / blood
  • Antioxidants / administration & dosage*
  • Apolipoprotein B-48 / blood
  • Apolipoprotein C-III / blood
  • Blood Glucose / metabolism
  • Body Mass Index
  • Cholesterol, HDL / blood
  • Cholesterol, LDL / blood
  • Diabetes Mellitus, Type 2 / blood
  • Diabetes Mellitus, Type 2 / drug therapy
  • Dietary Supplements*
  • Dinoprost / analogs & derivatives
  • Dinoprost / blood
  • Dose-Response Relationship, Drug
  • Double-Blind Method
  • Dyslipidemias / drug therapy*
  • Female
  • Humans
  • Insulin / blood
  • Insulin Resistance*
  • Linoleic Acids / blood
  • Male
  • Middle Aged
  • Nutrition Assessment
  • Oxidative Stress / drug effects
  • Triglycerides / blood

Substances

  • Anthocyanins
  • Antioxidants
  • Apolipoprotein B-48
  • Apolipoprotein C-III
  • Blood Glucose
  • Cholesterol, HDL
  • Cholesterol, LDL
  • Insulin
  • Linoleic Acids
  • Triglycerides
  • 8-epi-prostaglandin F2alpha
  • 13-hydroxy-9,11-octadecadienoic acid
  • Dinoprost
  • 3-Hydroxybutyric Acid

Associated data

  • ClinicalTrials.gov/NCT02317211